|22.61||+0.0200||+0.09%||Vol 64.81K||1Y Perf 12.86%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||30.92||Analyst Rating||Moderate Buy 1.67|
|Potential %||36.75||Finscreener Ranking||★★★★ 54.19|
|Insiders Trans % 3/6/12 mo.||-100/-100/-57||Value Ranking||★★★+ 54.38|
|Insiders Value % 3/6/12 mo.||-100/-100/-45||Growth Ranking||★★ 44.63|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-32||Income Ranking||— -|
|Market Cap||884.50M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||61.89||Earnings Date||29th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|3/2021 QR||-0.11||-1 000.00||Negative|
|Next Report Date||29th Apr 2021|
|Estimated EPS Next Report||-0.11|
|EPS Growth Next 5 Years %||2.00|
|Avg. Weekly Volume||84.00K|
|Avg. Monthly Volume||151.77K|
|Avg. Quarterly Volume||179.27K|
CryoLife Inc. (NYSE: CRY) stock closed at 22.61 per share at the end of the most recent trading day (a 0.09% change compared to the prior day closing price) with a volume of 64.86K shares and market capitalization of 884.50M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1200 people. CryoLife Inc. CEO is James Patrick Mackin.
The one-year performance of CryoLife Inc. stock is 12.86%, while year-to-date (YTD) performance is -4.24%. CRY stock has a five-year performance of 105.36%. Its 52-week range is between 16.13 and 26.6, which gives CRY stock a 52-week price range ratio of 61.89%
CryoLife Inc. currently has a PE ratio of -50.20, a price-to-book (PB) ratio of 2.69, a price-to-sale (PS) ratio of 4.70, a price to cashflow ratio of 69.10, a PEG ratio of 2.32, a ROA of -2.29%, a ROC of -0.02% and a ROE of -5.18%. The company’s profit margin is -5.18%, its EBITDA margin is 8.00%, and its revenue ttm is $186.80 Million , which makes it $4.78 revenue per share.
Of the last four earnings reports from CryoLife Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. CryoLife Inc.’s next earnings report date is 29th Apr 2021.
The consensus rating of Wall Street analysts for CryoLife Inc. is Moderate Buy (1.67), with a target price of $30.92, which is +36.75% compared to the current price. The earnings rating for CryoLife Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CryoLife Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CryoLife Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.45, ATR14 : 1.11, CCI20 : -85.80, Chaikin Money Flow : -0.06, MACD : 0.03, Money Flow Index : 49.02, ROC : -4.11, RSI : 47.53, STOCH (14,3) : 37.50, STOCH RSI : 0.34, UO : 44.20, Williams %R : -62.50), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CryoLife Inc. in the last 12-months were: Amy D. Horton (Option Excercise at a value of $132 920), Amy D. Horton (Sold 9 666 shares of value $209 918 ), David Ashley Lee (Option Excercise at a value of $166 160), David Ashley Lee (Sold 16 666 shares of value $383 318 ), Dennis B Maier (Option Excercise at a value of $142 877), Dennis B Maier (Sold 9 040 shares of value $218 226 ), James Patrick Mackin (Buy at a value of $125 524), James W Bullock (Buy at a value of $166 273), Jean F. Holloway (Sold 1 693 shares of value $42 797 ), John E. Davis (Buy at a value of $166 459), Ronald D. Mccall (Sold 8 076 shares of value $179 506 ), Scott B. Capps (Option Excercise at a value of $99 700), Scott B. Capps (Sold 8 366 shares of value $178 553 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.